Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 61

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ZELENECTIDE PEVEDOTIN
  • Sponsor:Bicycletx Limited

Idiopathic pulmonary fibrosis

Not recruiting

Study of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cystic fibrosis lung

Not recruiting

Safety and effectiveness study of inhaled ARCT-032 (mRNA therapy) in adults with Cystic Fibrosis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Arcturus Therapeutics Europe B.V.

Non-small cell lung cancer+5

Not recruiting

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:AIO-Studien gGmbH

Conjunctivitis allergic+1

Not recruiting

Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Phleum Pratense Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Conjunctivitis allergic+1

Not recruiting

Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Allergen Extract From Phleum Pratense Pollen, Glutaraldehyde-Modified
  • Sponsor:ROXALL Medizin GmbH

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine combinations compared to standard influenza vaccines in adults aged 18 and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Pneumonia bacterial+1

Not recruiting

Study evaluating blood biomarkers for diagnosis and monitoring treatment in patients with pulmonary tuberculosis using isoniazid, rifampicin, pyrazinamide, and ethambutol combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Isoniazid
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Respiratory syncytial virus infection+1

Not recruiting

Studying the Effect of Nirsevimab Immunization on Antibody Development After RSV Infection in Healthy Infants

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Small cell lung cancer

Not recruiting

Study of Durvalumab for Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Bronchopulmonary aspergillosis

Not recruiting

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rezafungin Acetate
  • Sponsor:Mundipharma Research Limited

Influenza

Not recruiting

Live Attenuated Influenza Vaccine (LAIV) and Immune Response in the Nasopharynx of Young Children with Influenza

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · Healthy volunteers
  • Substances:INFLUENZA VIRUS B/AUSTRIA/1359417/2021 - LIKE STRAIN (B/AUSTRIA/1359417/2021, MEDI 355292)
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.